目的 探讨毛细支气管炎患儿分子遗传学检验与哮喘的相关性及临床应用价值。方法 回顾性调查符合标准的2012年11月-2013年4月份间120例住院患儿, 住院均诊断为“毛细支气管炎”。患儿入院后均进行儿童过敏性哮喘遗传检测, 根据检测结果, 分析患儿的喘息次数与儿童过敏性检测高风险性是否有关。结果 1)第一次发病的毛细支气管炎患儿的儿童过敏性哮喘遗传检测遗传风险性明显低于第二次发病的毛细支气管炎患儿的儿童过敏性哮喘遗传检测遗传风险性, 差异有统计学意义(P<0.05)。2)治疗组患儿给予相应的抗哮喘治疗, 而对照组患儿给予常规治疗(毛细支气管炎治疗), 结果治疗组患儿的咳嗽、喘憋、呼吸困难及肺部啰音消失的时间及随后的发作次数, 住院时间, 经济费用及家庭压力明显低于对照组, 差异有统计学意义(P均<0.05)。结论 通过对毛细支气管炎婴幼儿进行儿童过敏性哮喘遗传检测, 从遗传角度上提示疾病的风险, 继而对高度遗传风险评估的婴幼儿进行抗哮喘干预治疗, 达到降低疾病风险的目的。

Objective To investigate the molecular genetics of bronchiolitis and asthma in test and clinical applications. Methods A retrospective compliant 120 cases of hospitalized children in hospital from November 2012 to April 2013 were diagnosed as "bronchiolitis".Children admitted to hospital were underwent genetic testing of children with allergic asthma, according to test results, the number of wheezing and high risk detection was analyzed. Results 1)The first incidence of bronchiolitis children with allergic asthma genetic testing genetic risk was significantly lower than the second incidence of bronchiolitis in children, there was significant difference (P<0.05).2)Children of treatment group were received the appropriate anti-asthma therapy, while the control group were treated with conventional therapy (bronchiolitis treatment), the cough, wheezing, dyspnea and pulmonary rales disappeared time and subsequent episodes, hospitalization time, economic costs and family pressure of the treatment group were significantly lower than those of the control group(P all <0.05). Conclusion Genetic testing for children allergic asthma of capillary bronchitis infants indicates the risk of disease from the genetic perspective, and asthma intervention treatment to high genetic risk assessment of infants and young children achieves the goal of lower disease risk.